Request Demo
Recent blog posts
Latest Hotspot
8 min read
Stapokibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Stapokibart: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661771 IMRT with Individualized Primary Clinical Target Volume Based on Margin Expansion Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661771, evaluating IMRT with Individualized Primary Clinical Target Volume Based on Margin Expansion in Nasopharyngeal Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Ivarmacitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ivarmacitinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661927 Removing Endocrine Therapy Early Stage Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661927, evaluating Removing Endocrine Therapy in Early Stage Breast Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07660796 Amlodipine/chlorthalidone/losartan Essential Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07660796, evaluating Amlodipine/chlorthalidone/losartan in Essential Hypertension: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Rabeprazole Sodium/Sodium Bicarbonate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Rabeprazole Sodium/Sodium Bicarbonate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07658339 HSK-39004 Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07658339, evaluating HSK-39004 in Pulmonary Disease, Chronic Obstructive: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Acetaminophen/Magnesium Oxide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Acetaminophen/Magnesium Oxide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661342 Radiation Therapy Dupuytren Contracture Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661342, evaluating Radiation Therapy in Dupuytren Contracture: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Acetaminophen/Vitamin B2 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Acetaminophen/Vitamin B2: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07659574 UBT-251 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659574, evaluating UBT-251 in Diabetes Mellitus, Type 2: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07659678 64CU-DOTA-ECL1i Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659678, evaluating 64CU-DOTA-ECL1i in Recurrent Squamous Cell Carcinoma of the Head and Neck: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.